MTA-304

Asset

Inhibition of phosphodiesterase 10A (PDE10A).

Stage
Phase 2
Modality
Small molecule
Target
PDE10A
1
Indication
0
Trials
1
Developer

Indications

1
  • Levodopa-induced dyskinesia in Parkinson's disease

    Phase 2, prnewswire.com, 7 Oct 2026

In the full profile

  • Targets and what it contains1
  • Owner and partners2
  • Evidence for its targets1
  • Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets